The number needed to treat estimates how many people receive treatment for one additional outcome to be prevented compared with a control group. The guide to what the SELECT trial counted as a cardiovascular event gives an example. A combined outcome includes events beyond heart attacks.[1]
What the pooled trials found
The review included 21 randomized trials of eight medications, including tirzepatide. Average follow-up across the trials was 2.4 years. The estimated number needed to treat was 66 for a trial-defined major cardiovascular event (incidence rate ratio 0.87, 95% CI 0.83–0.91). It was 121 for death from any cause and 170 for cardiovascular death.[1]
The same review found more gastrointestinal and gallbladder disorders in the treatment groups. The separate analysis of gallstones and reflux in randomized trials reports how those outcomes changed in absolute terms. They are different outcomes from those used to calculate the cardiovascular estimate.[1]
Why baseline risk and follow-up matter
The authors calculated these figures from absolute risk differences. One fewer event per 66 people compares the total number of events between groups. It does not identify which people benefited or capture other outcomes. A lower starting risk can mean a smaller absolute benefit even when the relative effect is the same.[1]
Participants included people with cardiovascular disease or risk factors such as diabetes, obesity, or kidney disease. Different studies used different follow-up periods and definitions of cardiovascular events. The pooled result should be read with those differences in mind.[1]